PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
/ 3 items
#CMPX↓
Craig-Hallum Bullish on Compass Therapeutics: Buy Rating & $15 Target
Investment firm Craig-Hallum starts coverage on Compass Therapeutics with a Buy rating and $15 price target, highlighting its promising bispecific antibody pipeline and potential blockbuster in biliary tract cancer.
Analyst Bullish Momentum Builds Around Compass Therapeutics
Multiple analysts initiate bullish coverage on Compass Therapeutics (CMPX), highlighting promising data for lead drug tovecimig and strong pipeline potential.